Shore Capital Reiterates Buy Rating for AstraZeneca (LON:AZN)

Key Points

• Shore Capital has reaffirmed a "buy" rating for AstraZeneca (LON:AZN) with a price objective of £135 ($180.36), indicating a potential upside of 23.09% from the current stock price.
• Other analysts, including Berenberg Bank and Deutsche Bank, have set price targets of GBX 140 ($1.87) and £110 ($146.96), respectively, with varying ratings on AstraZeneca's stock.
• AstraZeneca's stock opened at £109.68 ($146.53) and has a market capitalization of £211.03 billion, with a PE ratio of 30.06 and a 52-week range between GBX 9,573.51 ($127.90) and £133.88 ($178.86).

Shore Capital reissued their buy rating on shares of AstraZeneca (LON:AZN - Free Report) in a research report sent to investors on Tuesday, MarketBeat Ratings reports. Shore Capital currently has a £135 ($179.19) price target on the biopharmaceutical company's stock.

A number of other brokerages have also recently weighed in on AZN. Deutsche Bank Aktiengesellschaft reissued a "hold" rating and set a £110 ($146.00) price objective on shares of AstraZeneca in a research note on Tuesday, July 8th. Berenberg Bank reissued a "buy" rating and set a GBX 140 ($1.86) price objective on shares of AstraZeneca in a research note on Friday, May 16th.

AstraZeneca Price Performance

Shares of AZN traded down GBX 220 ($2.92) during mid-day trading on Tuesday, reaching £111.04 ($147.39). 1,861,434 shares of the company's stock were exchanged, compared to its average volume of 11,168,884. The company has a quick ratio of 0.59, a current ratio of 0.93 and a debt-to-equity ratio of 73.83. The company has a 50-day simple moving average of £105.77 and a two-hundred day simple moving average of £108.80. AstraZeneca has a 52-week low of GBX 9,573.51 ($127.07) and a 52-week high of £133.88 ($177.70). The company has a market cap of £213.64 billion, a price-to-earnings ratio of 30.44, a PEG ratio of 0.86 and a beta of 0.17.

About AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.